YSPSL (rPSGL‐Ig) for improvement of early renal allograft function: a double‐blind, placebo‐controlled, multi‐center Phase IIa study1,2,3
Year: 2010
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Clinical Transplantation
Authors: A. Osama Gaber, Shamkant Mulgaonkar, Barry D. Kahan, E. Steve Woodle, Rita Alloway, Iman Bajjoka, Stephen Jensik, Goran B. Klintmalm, Pamela R. Patton, Alexander Wiseman, Gerald Lipshutz, Jerzy Kupiec‐Weglinski, Lilian W. Gaber, Eliezer Katz, William Irish, Elizabeth C. Squiers, Stefan Hemmerich
Institutions: Houston Methodist, Saint Barnabas Medical Center, University of Cincinnati, Henry Ford Hospital, Rush University Medical Center, Baylor University Medical Center, University of Florida Health, University of Florida, University of Colorado Denver, University of California, Los Angeles, Clinical Trial and Consulting, Nano Hydrophobics (United States)
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2087353256